Equities research analysts expect that Zimmer Biomet Holdings Inc (NYSE:ZBH) will post $1.60 earnings per share (EPS) for the current quarter, according to Zacks. Eleven analysts have issued estimates for Zimmer Biomet’s earnings. The lowest EPS estimate is $1.56 and the highest is $1.67. Zimmer Biomet reported earnings per share of $1.72 in the same quarter last year, which would suggest a negative year over year growth rate of 7%. The company is scheduled to announce its next earnings report on Wednesday, November 7th.

On average, analysts expect that Zimmer Biomet will report full-year earnings of $7.66 per share for the current year, with EPS estimates ranging from $7.60 to $7.74. For the next financial year, analysts expect that the business will post earnings of $7.95 per share, with EPS estimates ranging from $7.90 to $8.05. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Zimmer Biomet.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Friday, July 27th. The medical equipment provider reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.88 by $0.04. The business had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.99 billion. Zimmer Biomet had a net margin of 21.67% and a return on equity of 13.53%. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.08 EPS.

A number of analysts have weighed in on the stock. Oppenheimer reissued a “buy” rating on shares of Zimmer Biomet in a research report on Monday, August 27th. Needham & Company LLC reissued a “buy” rating and set a $150.00 target price on shares of Zimmer Biomet in a research report on Monday, August 27th. Cantor Fitzgerald reissued a “buy” rating and set a $150.00 target price on shares of Zimmer Biomet in a research report on Monday, August 27th. BTIG Research assumed coverage on shares of Zimmer Biomet in a research report on Thursday, August 16th. They set a “neutral” rating for the company. Finally, Citigroup increased their target price on shares of Zimmer Biomet from $117.00 to $128.00 and gave the company a “neutral” rating in a research report on Tuesday, July 31st. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and fifteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $135.10.

In other Zimmer Biomet news, CEO Bryan C. Hanson purchased 410 shares of Zimmer Biomet stock in a transaction that occurred on Friday, August 31st. The stock was acquired at an average price of $123.03 per share, with a total value of $50,442.30. Following the transaction, the chief executive officer now owns 25,487 shares in the company, valued at approximately $3,135,665.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Tony W. Collins sold 2,778 shares of Zimmer Biomet stock in a transaction on Tuesday, July 31st. The shares were sold at an average price of $125.77, for a total transaction of $349,389.06. The disclosure for this sale can be found here. Company insiders own 0.71% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of ZBH. Whittier Trust Co. of Nevada Inc. lifted its stake in Zimmer Biomet by 18.4% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 3,773 shares of the medical equipment provider’s stock valued at $392,000 after acquiring an additional 586 shares in the last quarter. E&G Advisors LP bought a new position in Zimmer Biomet during the 2nd quarter valued at $490,000. Mitsubishi UFJ Asset Management UK Ltd. lifted its stake in Zimmer Biomet by 44.9% during the 2nd quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 12,900 shares of the medical equipment provider’s stock valued at $1,656,000 after acquiring an additional 4,000 shares in the last quarter. Grandfield & Dodd LLC lifted its stake in Zimmer Biomet by 2.5% during the 2nd quarter. Grandfield & Dodd LLC now owns 124,167 shares of the medical equipment provider’s stock valued at $13,837,000 after acquiring an additional 3,033 shares in the last quarter. Finally, UMB Bank N A MO lifted its stake in Zimmer Biomet by 4.5% during the 2nd quarter. UMB Bank N A MO now owns 10,467 shares of the medical equipment provider’s stock valued at $1,167,000 after acquiring an additional 455 shares in the last quarter. 87.22% of the stock is owned by institutional investors and hedge funds.

NYSE:ZBH traded down $0.51 on Wednesday, reaching $129.56. 66,859 shares of the stock traded hands, compared to its average volume of 877,207. The company has a market capitalization of $25.68 billion, a PE ratio of 16.14, a P/E/G ratio of 2.31 and a beta of 1.09. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.25 and a current ratio of 2.41. Zimmer Biomet has a 1-year low of $104.28 and a 1-year high of $130.58.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 31st. Stockholders of record on Friday, September 28th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.74%. The ex-dividend date is Thursday, September 27th. Zimmer Biomet’s dividend payout ratio (DPR) is 11.96%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Recommended Story: How is an ETF different from a mutual fund?

Get a free copy of the Zacks research report on Zimmer Biomet (ZBH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.